June 9, 2020 -- Twist Bioscience has joined forces with Serimmune to identify and evaluate SARS-CoV-2 therapeutic antibody candidates.
Existing Twist antibody candidates that bind with high affinity to either the SARS-CoV-2 S1 spike protein or the human angiotensin-converting enzyme 2 (ACE2) cellular receptor will be evaluated using Serimmune's Serum Epitope Repertoire Analysis (SERA) platforms. Those epitopes that are identified in the first phase of the collaboration will then be used to rescreen Twist's proprietary synthetic antibody discovery libraries to identify and evaluate new candidates, while also further increasing the specificity of antibody candidates, according to the companies.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: